ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/10/13 | $10,600,000 | Series C-1 |
Asset Management Ventures Johnson & Johnson Innovation Sanderling Ventures | undisclosed |
| 08/08/14 | $5,400,000 | Series C-1 | ||
| 08/25/14 | $20,000,000 |
Janssen Research & Development | undisclosed | |
| 11/30/18 | $80,000,000 | Series D |
Bain Capital RA Capital Management Sanderling Ventures TPG | undisclosed |
